Industry Daily Summary
Industry Daily Summary: What Happened on October 11, 2026
The Niche weighs stem-cell oversight debate and biotech disputes
The commentary argues that FDA rules for cell therapies have grown clearer, while noting a reported $20 billion valuation for Colossal.
Today in brief
The Niche author reviewed disputes over stem-cell oversight and biotech figures’ social-media exchanges, and cited a reported $20 billion valuation for Colossal.1
Stem-cell oversight and biotech disputes
The Niche author argues that FDA rules for stem-cell and other cell therapies have become clearer over the past five to 10 years, contrary to claims from the clinic sector.1 The author says the FDA has repeatedly sent warning letters to stem-cell clinics and suppliers, including firms associated with R3 Stem Cell.1
The author says stem-cell and peptide products are increasingly promoted by the same businesses, which may benefit if FDA oversight of stem cells weakens.1 The author also says there are reports that Kennedy may be pressing CBER to ease oversight of stem-cell clinics, but doubts that process would be as simple as the peptide policy changes underway.1
A recent Colossal financing round reportedly placed the company’s valuation at $20 billion.1